On reversing the persistence of memory: Hematopoietic stem cell transplant for autoimmune disease in the first ten years

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

There has been a remarkable history in the treatment of patients with autoimmune disease in the last century. Prior to the development of newer NSAIDs and corticosteroids, the care of patients with autoimmune disease was limited to aspirin and generally homeopathic therapies such as paraffin. In the last 30 years, the introduction and acceptance of cytotoxic drugs such as methotrexate and cyclophosphamide have greatly advanced the treatment of patients with severe autoimmune diseases. However, the use and dose escalation of cytotoxic agents in severely ill patients is limited by toxicity and the potential for secondary malignancies that correlate with cumulative lifetime dosing. As hematopoietic stem cell transplant grew to become an established procedure for certain malignancies, reports of remission of coexistent autoimmune diseases began to emerge. Animal data subsequently supported a role for hematopoietic stem cell transplants for the primary indication of autoimmune diseases. On the basis of these reports, clinical trials of hematopoietic stem cell transplants for the primary indication of autoimmune disease were initiated in the late 1990s. We review the data from a decade of experience that has now accumulated for this novel approach to the management of autoimmunity.

Original languageEnglish (US)
Pages (from-to)180-196
Number of pages17
JournalJournal of Autoimmunity
Volume30
Issue number3
DOIs
StatePublished - May 2008

Fingerprint

Hematopoietic Stem Cells
Autoimmune Diseases
Transplants
Cytotoxins
Non-Steroidal Anti-Inflammatory Agents
Autoimmunity
Methotrexate
Paraffin
Cyclophosphamide
Aspirin
Neoplasms
Patient Care
Adrenal Cortex Hormones
Therapeutics
History
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Autoimmune diseases
  • Autoimmunity
  • Bone marrow transplant
  • Hematopoietic stem cell transplant
  • Stem cell

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{57848e6504074b71bbb271f7b90ede4a,
title = "On reversing the persistence of memory: Hematopoietic stem cell transplant for autoimmune disease in the first ten years",
abstract = "There has been a remarkable history in the treatment of patients with autoimmune disease in the last century. Prior to the development of newer NSAIDs and corticosteroids, the care of patients with autoimmune disease was limited to aspirin and generally homeopathic therapies such as paraffin. In the last 30 years, the introduction and acceptance of cytotoxic drugs such as methotrexate and cyclophosphamide have greatly advanced the treatment of patients with severe autoimmune diseases. However, the use and dose escalation of cytotoxic agents in severely ill patients is limited by toxicity and the potential for secondary malignancies that correlate with cumulative lifetime dosing. As hematopoietic stem cell transplant grew to become an established procedure for certain malignancies, reports of remission of coexistent autoimmune diseases began to emerge. Animal data subsequently supported a role for hematopoietic stem cell transplants for the primary indication of autoimmune diseases. On the basis of these reports, clinical trials of hematopoietic stem cell transplants for the primary indication of autoimmune disease were initiated in the late 1990s. We review the data from a decade of experience that has now accumulated for this novel approach to the management of autoimmunity.",
keywords = "Autoimmune diseases, Autoimmunity, Bone marrow transplant, Hematopoietic stem cell transplant, Stem cell",
author = "Sean Deane and Meyers, {Frederick J} and Gershwin, {M. Eric}",
year = "2008",
month = "5",
doi = "10.1016/j.jaut.2007.12.001",
language = "English (US)",
volume = "30",
pages = "180--196",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - On reversing the persistence of memory

T2 - Hematopoietic stem cell transplant for autoimmune disease in the first ten years

AU - Deane, Sean

AU - Meyers, Frederick J

AU - Gershwin, M. Eric

PY - 2008/5

Y1 - 2008/5

N2 - There has been a remarkable history in the treatment of patients with autoimmune disease in the last century. Prior to the development of newer NSAIDs and corticosteroids, the care of patients with autoimmune disease was limited to aspirin and generally homeopathic therapies such as paraffin. In the last 30 years, the introduction and acceptance of cytotoxic drugs such as methotrexate and cyclophosphamide have greatly advanced the treatment of patients with severe autoimmune diseases. However, the use and dose escalation of cytotoxic agents in severely ill patients is limited by toxicity and the potential for secondary malignancies that correlate with cumulative lifetime dosing. As hematopoietic stem cell transplant grew to become an established procedure for certain malignancies, reports of remission of coexistent autoimmune diseases began to emerge. Animal data subsequently supported a role for hematopoietic stem cell transplants for the primary indication of autoimmune diseases. On the basis of these reports, clinical trials of hematopoietic stem cell transplants for the primary indication of autoimmune disease were initiated in the late 1990s. We review the data from a decade of experience that has now accumulated for this novel approach to the management of autoimmunity.

AB - There has been a remarkable history in the treatment of patients with autoimmune disease in the last century. Prior to the development of newer NSAIDs and corticosteroids, the care of patients with autoimmune disease was limited to aspirin and generally homeopathic therapies such as paraffin. In the last 30 years, the introduction and acceptance of cytotoxic drugs such as methotrexate and cyclophosphamide have greatly advanced the treatment of patients with severe autoimmune diseases. However, the use and dose escalation of cytotoxic agents in severely ill patients is limited by toxicity and the potential for secondary malignancies that correlate with cumulative lifetime dosing. As hematopoietic stem cell transplant grew to become an established procedure for certain malignancies, reports of remission of coexistent autoimmune diseases began to emerge. Animal data subsequently supported a role for hematopoietic stem cell transplants for the primary indication of autoimmune diseases. On the basis of these reports, clinical trials of hematopoietic stem cell transplants for the primary indication of autoimmune disease were initiated in the late 1990s. We review the data from a decade of experience that has now accumulated for this novel approach to the management of autoimmunity.

KW - Autoimmune diseases

KW - Autoimmunity

KW - Bone marrow transplant

KW - Hematopoietic stem cell transplant

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=39149118881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149118881&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2007.12.001

DO - 10.1016/j.jaut.2007.12.001

M3 - Article

C2 - 18242059

AN - SCOPUS:39149118881

VL - 30

SP - 180

EP - 196

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 3

ER -